NewAmsterdam Pharma Company NV - Warrants (15/11/2027)
NAMSW
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.63B
Close$
$3.09
73.4% downside
Current Fair Value
73.4% downsideOvervalued by 73.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.63 Billion |
|---|---|
| Enterprise Value | $2.21 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.11 |
| Outstanding Shares | 123,370,232 |
Return
| Return on Equity | -41.10% |
|---|---|
| Return on Assets | -36.84% |
| Return on Invested Capital | -40.57% |
Valuation & Multiples
| P/E Ratio | -10.32 |
|---|---|
| PEG | -3.83 |
| Price to Sales | - |
| Price to Book Ratio | 2.33 |
| Enterprise Value to Revenue | 310.05 |
| Enterprise Value to EBIT | -8.62 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$7.54 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data